Mechanisms of diabetes-induced liver damage: The role of oxidative stress and inflammation

Sultan Qaboos University Medical Journal

Volumn 16, Issue 2, 2016, Pages e132-e141

  Mohamed, Jamaludin ^a   Nazratun Nafizah, A H ^a   Zariyantey, A H ^a   Budin, S B ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Diabetes mellitus; Inflammation; Liver diseases; Oxidative stress

Indexed keywords

EID: 84967103665     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: 10.18295/squmj.2016.16.02.002     Document Type: Review

References (57)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 31-40. doi: 10.1016/s0140-6736(11)60679-x.
2. Reid AE. Non-alcoholic fatty liver disease. In: Feldman M, Friedman LS, Brandt LJ, Eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology/diagnosis/management, 8th ed. St. Louis, Missouri, USA: Saunders, 2006. Pp. 1772-99.
3. Levinthal GN, Tavill AS. Liver disease and diabetes mellitus. Clin Diabetes 1999; 17: 73.
4. Guven A, Yavuz O, Cam M, Ercan F, Bukan N, Comunoglu C, et al. Effects of melatonin on streptozotocin-induced diabetic liver injury in rats. Acta Histochem 2006; 108: 85-93. doi: 10.1016/j.acthis.2006.03.005.
5. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat? J Hepatol 2006; 44: 253-61. doi: 10.1016/j.jhep.2005.11.030.
6. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences. J Hepatol 2007; 47: 142-56. doi: 10.1016/j.jhep.2007.04.002.
7. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatology 2005; 42: 987-1000. doi: 10.1002/hep.20920.
8. Manna P, Das J, Ghosh J, Sil PC. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid. Free Radic Biol Med 2010; 48: 1465-84. doi: 10.1016/j.freeradbiomed.2010.02.025.
9. Palsamy P, Sivakumar S, Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem Biol Interact 2010; 186: 200-10. doi: 10.1016/j. cbi.2010.03.028.
10. Romagnoli M, Gomez-Cabrera MC, Perrelli MG, Biasi F, Pallardó FV, Sastre J, et al. Xanthine oxidase-induced oxidative stress causes activation of NF-kappaB and inflammation in the liver of type I diabetic rats. Free Radic Biol Med 2010; 49: 171-7. doi: 10.1016/j.freeradbiomed.2010.03.024.
11. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: E526-31. doi: 10.1503/cmaj.092144.
12. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: Old questions and new insights. Science 2011; 332: 1519-23. doi: 10.1126/science.1204265.
13. Crawford JM, Iacobuzio-Donahue C. Liver and biliary tract. In: Kumar V, Abbas AK, Fausto N, Aster JC, Eds. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, Pennsylvania, USA: Saunders, 2009. Pp. 833-90.
14. Al-Hussaini AA, Sulaiman NM, Alzahrani MD, Alenizi AS, Khan M. Prevalence of hepatopathy in type 1 diabetic children. BMC Pediatr 2012; 12: 160. doi: 10.1186/1471-2431-12-160.
15. Regnell SE, Lernmark Å. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011; 8: 454-67. doi: 10.1900/rds.2011.8.454.
16. Welt K, Weiss J, Martin R, Dettmer D, Hermsdorf T, Asayama K, et al. Ultrastructural, immunohistochemical and biochemical investigations of the rat liver exposed to experimental diabetes and acute hypoxia with and without application of Ginkgo extract. Exp Toxicol Pathol 2004; 55: 331-45. doi: 10.1078/0940-2993-00337.
17. Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: An ominous association. Nutr Metab Cardiovasc Dis 2007; 17: 63-70. doi: 10.1016/j.numecd.2006.08.004.
18. Hamden K, Carreau S, Boujbiha MA, Lajmi S, Aloulou D, Kchaou D, et al. Hyperglycaemia, stress oxidant, liver dysfunction and histological changes in diabetic male rat pancreas and liver: Protective effect of 17 beta-estradiol. Steroids 2008; 73: 495-501. doi: 10.1016/j.steroids.2007.12.026.
19. Lucchesi AN, Cassettari LN, Spadella CT. Alloxan-induced diabetes causes morphological and ultrastructural changes in rat liver that resemble the natural history of chronic fatty liver disease in humans. J Diabetes Res 2015; 2015: 494578. doi: 10.1155/2015/494578.
20. Mavrogiannaki AN, Migdalis IN. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: Newer data. Int J Endocrinol 2013; 2013: 450639. doi: 10.1155/2013/450639.
21. Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. Volume 2, 18th ed. New York, USA: McGraw-Hill, 2011.
22. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: The Mexico City diabetes study. Diabetes Care 2005; 28: 1757-62. doi: 10.2337/diacare.28.7.1757.
23. Elsheikh E, Henry LL, Younossi ZM. Current management of patients with nonalcoholic fatty liver disease. Expert Rev Endocrinol Metab 2013; 8: 549-58. doi: 10.1586/17446651.2013.846212.
24. Stefan N, Sun Q, Fritsche A, Machann J, Schick F, Gerst F, et al. Impact of the adipokine adiponectin and the hepatokine fetuin-A on the development of type 2 diabetes: Prospective cohort-and cross-sectional phenotyping studies. PLoS One 2014; 9: e92238. doi: 10.1371/journal.pone.0092238.
25. Iroz A, Couty JP, Postic C. Hepatokines: Unlocking the multiorgan network in metabolic diseases. Diabetologia 2015; 58: 1699-1703. doi: 10.1007/s00125-015-3634-4.
26. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15: 280-8. doi: 10.3748/wjg.15.280.
27. Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res 2009; 37: 2539-48. doi: 10.1093/nar/gkp100.
28. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-8. doi: 10.1016/j.jhep.2012.08.018.
29. Wei Y, Chen P, de Bruyn MD, Zhang W, Bremer E, Helfrich W. Carbon monoxide-releasing molecule-2 (CORM-2) attenuates acute hepatic ischemia reperfusion injury in rats. BMC Gastroenterol 2010; 10: 42. doi: 10.1186/1471-230X-10-42.
30. Parveen K, Khan MR, Mujeeb M, Siddigui WA. Protective effects of Pycnogenol on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats. Chem Biol Interact 2010; 186: 219-27. doi: 10.1016/j.cbi.2010.04.023.
31. Han D, Hanawa N, Saberi B, Kaplowitz N. Mechanisms of liver injury: III - Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1-7. doi: 10.1152/ajpgi.00001.2006.
32. Ahmed N. Advanced glycation endproducts: Role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21. doi: 10.1016/j.diabres.2004.09.004.
33. Horiuchi S. The liver is the main site for metabolism of circulating advanced glycation end products. J Hepatol 2002; 36: 123-5. doi: 10.1016/S0168-8278(01)00293-8.
34. Yagmur E, Tacke F, Weiss C, Lahme B, Manns MP, Keifer P, et al. Elevation of Nepsilon-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis. Clin Biochem 2006; 39: 39-45. doi: 10.1016/j.clinbiochem.2005.07.016.
35. Ahmed N, Thornalley PJ, Lüthen R, Häussinger D, Sebekova K, Schinzel R, et al. Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis. J Hepatol 2004; 41: 913-19. doi: 10.1016/j.jhep.2004.08.007.
36. Zuwała-Jagiełło J, Pazgan-Simon M, Simon K, Warwas M. Elevated advanced oxidation protein products levels in patients with liver cirrhosis. Acta Biochim Pol 2009; 56: 679-85.
37. Sebeková K, Kupcová V, Schinzel R, Heidland A. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis: Amelioration by liver transplantation. J Hepatol 2002; 36: 66-71. doi: 10.1016/S0168-8278(01)00232-X.
38. Shacter E. Quantification and significance of protein oxidation in biological samples. Drug Metab Rev 2000; 32: 307-26. doi: 10.1081/DMR-100102336.
39. Abdelmegeed MA, Song BJ. Functional roles of protein nitration in acute and chronic liver diseases. Oxid Med Cell Longev 2014; 2014: 149627. doi: 10.1155/2014/149627.
40. Witko-Sarsat V, Friendlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
41. Nazratun N, Mahmood AA, Kuppusamy UR, Ahmad TS, Tan SY. Diabetes mellitus exacerbates advanced glycation end product accumulation in the veins of end-stage renal failure patients. Vasc Med 2006; 11: 245-50. doi: 10.1177/1358863x06072202.
42. Iwao Y, Anraku M, Hiraike M, Kawai K, Nakajou K, Kai T, et al. The structural and pharmacokinetic properties of oxidized human serum albumin, advanced oxidation protein products (AOPP). Drug Metab Pharmacokinet 2006; 21: 140-6. doi: 10.2133/dmpk.21.140.
43. Svistounov D, Smedsrød B. Hepatic clearance of advanced glycation end products (AGEs): Myth or truth? J Hepatol 2004; 41: 1038-40. doi: 10.1016/j.jhep.2004.10.004.
44. McNuff MA, Omoruyi FO, Morrison EY, Asemota HN. Hepatic function enzymes and lipid peroxidation in streptozotocininduced diabetic rats fed bitter yam (Dioscorea polygonoides) steroidal sapogenin extract. Diabetol Croat 2003; 32: 17-23.
45. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007; 131: 1728-34.
46. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes Complications 2012; 26: 483-90. doi: 10.1016/j.jdiacomp.2012.06.001.
47. Ugochukwu NH, Figgers CL. Dietary caloric restriction modifies inflammatory responses in the livers of streptozotocininduced diabetic rats. Nutr Res 2006; 26: 221-6. doi: 10.1016/j. nutres.2006.05.003.
48. Seven A, Guzel S, Seymen O, Civelek S, Bolayirli M, Uncu M, et al. Effects of vitamin E supplementation on oxidative stress in streptozotocin induced diabetic rats: Investigation of liver and plasma. Yonsei Med J 2004; 45: 703-10. doi: 10.3349/ ymj.2004.45.4.703.
49. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: Role in type 2 diabetes. Clin Chim Acta 2012; 413: 1163-70. doi: 10.1016/j.cca.2012.03.021.
50. Martínez-Flórez S, Gutiérrez-Fernández B, Sánchez-Campos S, González-Gallego J, Tuñón MJ. Quercetin attenuates nuclear factor-kappaB activation and nitric oxide production in interleukin-1beta-activated rat hepatocytes. J Nutr 2005; 135: 1359-65.
51. Arsura M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 2005; 229: 157-69. doi: 10.1016/j. canlet.2005.07.008.
52. Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: Focusing on the role of stress-activated MAPK. Patholog Res Int 2012; 2012: 172894. doi: 10.1155/2012/172894.
53. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013; 36: S127-38. doi: 10.2337/dcS13-2011.
54. Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006; 82: 315-22. doi: 10.1136/ pgmj.2005.042200.
55. Kim HY, Okamoto T, Yokozawa T. Beneficial effects of Chinese prescription Kangen-karyu on diabetes associated with hyperlipidemia, advanced glycation endproducts, and oxidative stress in streptozotocin-induced diabetic rats. J Ethnopharmacol 2009; 124: 263-9. doi: 10.1016/j.jep.2009.04.032.
56. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 2003; 17: 24-38. doi: 10.1002/jbt.10058.
57. Jain SK, Velusamy T, Croad JL, Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, oxidative stress and inhibits NFkappaB activation in the livers of Zucker diabetic rats. Free Radic Biol Med 2009; 46: 1633-38. doi: 10.1016/j.freeradbiomed.2009.03.014.